Copyright
©2014 Baishideng Publishing Group Inc.
World J Cardiol. Aug 26, 2014; 6(8): 706-712
Published online Aug 26, 2014. doi: 10.4330/wjc.v6.i8.706
Published online Aug 26, 2014. doi: 10.4330/wjc.v6.i8.706
Ref. | Sample size | Follow up duration | Mean SBP reduction in RDN group (in mmHg) | Mean SBP reduction in control group (in mmHg) | P value |
Worthley et al[22] (EnilgHTN 1 trial) | 46 | 6 mo | 26 | No randomized control group | 0.0001 |
a Krum et al[28] | 45 | 12 mo | 27 | No randomized control group | 0.001 |
Simplicity HTN-1 investigatorsb | 153 | 24 mo | 32 | No randomized control group | 0.0001 |
Esler et al[12] (Simplicity HTN-2) | 106 | 6 mo | 32 ± 23 | + 1 | 0.0001 |
Bhatt et al[32] ( Symplicity HTN-3) | 535 | 6 mo | 14.13 ± 23.93 | 11.74 ± 25.94 | < 0.001 |
- Citation: Lokhandwala A, Dhoble A. Transcatheter therapies for resistant hypertension: Clinical review. World J Cardiol 2014; 6(8): 706-712
- URL: https://www.wjgnet.com/1949-8462/full/v6/i8/706.htm
- DOI: https://dx.doi.org/10.4330/wjc.v6.i8.706